India today unarguably is the most favoured destination for the pharmaceutical R&D
and clinical research The key reasons area:
- 100 million plus English speaking people (Largest outside US)
- Over 2 million science post graduates
- Large pool of treatment- naïve patients from multiethnic and multiracial backgrounds
- Easy patient recruitment and compliance
- Favourable Regulatory Policies – Updated Schedule Y
- IPR / WTO, GATT on board
- Cost effective business operations
- International regulatory approvals for GMP/GLP/GCP
- Maximum number of approved GMP plants outside USA
- Excellent quality management, Technology and infrastructure
- Time zone difference facilities 24/7 support
- Presence of all Pharma major & also in-house CROs set up by leading pharma
companies
- Presence of all leading international CROs and several domestic CROs – over 75
CROs
- Strong IT industry availability of IT skilled manpower
- 30 million patients with cardiovascular diseases
- 25 million with Type 2 diabetes
- 10 million with psychiatric disorders
- 2 million cases of cancer with 500,000 cases detected every year
- 600,000 practicing physicians
- 14,000 hospitals
- 700,000 beds
- 17,000 medical graduates per year